Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24378943 | 0.88 | PTPN11 (0.68) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL24379052 | 0.86 | PTPN11 (0.47) | PTPN11KCNH2 | |
| SCHEMBL24181645 | 0.85 | PTPN11 (0.62) | PTPN11KCNH2MAPK3MAPK1CDK4 | |
| SCHEMBL24181560 | 0.84 | PTPN11 (0.59) | PTPN11KCNH2MAPK3MAPK1CDK4 | |
| SCHEMBL24181829 | 0.84 | PTPN11 (0.59) | PTPN11KCNH2MAPK3MAPK1CDK4 | |
| SCHEMBL24181554 | 0.84 | PTPN11 (0.59) | PTPN11KCNH2MAPK3MAPK1CDK4 | |
| SCHEMBL24378938 | 0.83 | PTPN11 (0.60) | PTPN11KCNH2MAPK3MAPK1CDK4 | |
| SCHEMBL24181990 | 0.83 | PTPN11 (0.62) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL24181705 | 0.83 | PTPN11 (0.62) | PTPN11KCNH2MAPK3MAPK1CDK4 | |
| SCHEMBL24181679 | 0.83 | PTPN11 (0.72) | PTPN11MAPK3MAPK1CDK4CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827644-B2 | Pyrazine derivative and application thereof in inhibiting SHP2 | SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD (CN) | 2023-11-28 | — | — | US | disclosed |
| US-11827644-B2 | Pyrazine derivative and application thereof in inhibiting SHP2 | SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD (CN) | 2023-11-28 | — | — | US | disclosed |
| US-20230227464-A1 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 | SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227464-A1 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 | SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20220127276-A1 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 | SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD (CN) | 2022-04-28 | — | — | US | disclosed |
| EP-3936502-A1 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 | Suzhou Genhouse Pharmaceutical Co., Ltd. (CN) | 2022-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827644-B2 | Pyrazine derivative and application thereof in inhibiting SHP2 | PTPN5, PTPN1, PTPN7 | PTPN11 7/4885KCNH2 3281/4885MAPK3 209/4885 |
| US-20220127276-A1 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 | PTPN5, PTPN1, PTPN7 | PTPN11 7/4885KCNH2 3281/4885MAPK3 209/4885 |
| US-20230227464-A1 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 | PTPN5, PTPN1, PTPN7 | PTPN11 7/4885KCNH2 3281/4885MAPK3 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.